Online inquiry

IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3957MR)

This product GTTS-WQ3957MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&FCRL5 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_000733.4; NM_001195388.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 83416
UniProt ID P07766; Q96RD9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3957MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1841MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AG1-25
GTTS-WQ13083MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-00547659
GTTS-WQ8922MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ4162MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BI-754091
GTTS-WQ7206MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
GTTS-WQ11232MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI3902
GTTS-WQ7471MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GBR-830
GTTS-WQ15495MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA UCB-7665
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW